15:03 | 13/03/2020 Science - Technology
(VEN) - The Ho Chi Minh City Diabetes and Endocrinology Association collaborated with AstraZeneca to host a webinar on significant benefits of SGLT2i class in type 2 diabetes management. The discussion focused on DECLARE clinical study, which clearly demonstrated the reduction of proteinuria progression on patients with type 2 diabetes using SGLT2i class.
The new approach can help their kidneys revert to a healthy stage early. Noticeably, early screening of kidney functions for patients with diabetes, including proteinuria, is recommended in latest treatment guidelines such as the treatment guidelines of American Diabetes Association (ADA 2020).
Led by Assoc. Prof. Nguyen Thy Khue, MD, PhD - President of the Ho Chi Minh City Diabetes and Endocrinology Association and Assoc. Prof. David Cherney, MD, PhD - a reputable Nephrologist and Scientist from the University of Toronto, Canada, the webinar attracted over 500 healthcare professionals nationwide. Celebrating the annual World Kidney Day on March 12, the webinar also spreaded the call for early detection and treatment of patients with diabetes to minimize complications on hearts and kidneys. The introduction of a new medication in SGLT2i class is positive news for the medical community and patients.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.